Buchumschlag

A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation: PROTECT

Posttransplant immunosuppression with calcineurin inhibitors (CNIs) is associated with impaired renal function, while mTor inhibitors such as everolimus may provide a renal-sparing alternative. In this randomized 1-year study in patients with liver transplantation (LTx), we sought to assess the effe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fischer, Lutz (VerfasserIn) , Schemmer, Peter (VerfasserIn) , Schmidt, Jan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 2012
In: American journal of transplantation
Year: 2012, Jahrgang: 12, Heft: 7, Pages: 1855-1865
ISSN:1600-6143
DOI:10.1111/j.1600-6143.2012.04049.x
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1111/j.1600-6143.2012.04049.x
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-6143.2012.04049.x
Volltext
Verfasserangaben:L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, P. Schemmer, U. Settmacher, N. Heyne, P.-A. Clavien, F. Muehlbacher, I. Morard, H. Wolters, W. Vogel, T. Becker, M. Sterneck, F. Lehner, C. Klein, G. Kazemier, A. Pascher, J. Schmidt, F. Rauchfuss, A. Schnitzbauer, S. Nadalin, M. Hack, S. Ladenburger and H.J. Schlitt

MARC

LEADER 00000caa a2200000 c 4500
001 1583833897
003 DE-627
005 20230427161319.0
007 cr uuu---uuuuu
008 181119s2012 xx |||||o 00| ||eng c
024 7 |a 10.1111/j.1600-6143.2012.04049.x  |2 doi 
035 |a (DE-627)1583833897 
035 |a (DE-576)513833897 
035 |a (DE-599)BSZ513833897 
035 |a (OCoLC)1341023753 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fischer, Lutz  |e VerfasserIn  |0 (DE-588)1027385249  |0 (DE-627)729053660  |0 (DE-576)373188919  |4 aut 
245 1 2 |a A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation  |b PROTECT  |c L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, P. Schemmer, U. Settmacher, N. Heyne, P.-A. Clavien, F. Muehlbacher, I. Morard, H. Wolters, W. Vogel, T. Becker, M. Sterneck, F. Lehner, C. Klein, G. Kazemier, A. Pascher, J. Schmidt, F. Rauchfuss, A. Schnitzbauer, S. Nadalin, M. Hack, S. Ladenburger and H.J. Schlitt 
264 1 |c July 2012 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.07.2019 
520 |a Posttransplant immunosuppression with calcineurin inhibitors (CNIs) is associated with impaired renal function, while mTor inhibitors such as everolimus may provide a renal-sparing alternative. In this randomized 1-year study in patients with liver transplantation (LTx), we sought to assess the effects of everolimus on glomerular filtration rate (GFR) after conversion from CNIs compared to continued CNI treatment. Eligible study patients received basiliximab induction, CNI with/without corticosteroids for 4 weeks post-LTx, and were then randomized (if GFR > 50 mL/min) to continued CNIs (N = 102) or subsequent conversion to EVR (N = 101). Mean calculated GFR 11 months postrandomization (ITT population) revealed no significant difference between treatments using the Cockcroft-Gault formula (−2.9 mL/min in favor of EVR, 95%-CI: [−10.659; 4.814], p = 0.46), whereas use of the MDRD formula showed superiority for EVR (−7.8 mL/min, 95%-CI: [−14.366; −1.191], p = 0.021). Rates of mortality (EVR: 4.2% vs. CNI: 4.1%), biopsy-proven acute rejection (17.7% vs. 15.3%), and efficacy failure (20.8% vs. 20.4%) were similar. Infections, leukocytopenia, hyperlipidemia and treatment discontinuations occurred more frequently in the EVR group. No hepatic artery thrombosis and no excess of wound healing impairment were noted. Conversion from CNI-based to EVR-based immunosuppression proved to be a safe alternative post-LTx that deserves further investigation in terms of nephroprotection. 
650 4 |a Calcineurin inhibitor agents 
650 4 |a conversion 
650 4 |a everolimus 
650 4 |a Liver transplantation 
650 4 |a mTor inhibitor 
650 4 |a renal function 
700 1 |a Schemmer, Peter  |d 1967-  |e VerfasserIn  |0 (DE-588)1022604244  |0 (DE-627)717006794  |0 (DE-576)365668230  |4 aut 
700 1 |a Schmidt, Jan  |d 1961-  |e VerfasserIn  |0 (DE-588)1022937995  |0 (DE-627)717335852  |0 (DE-576)366198017  |4 aut 
773 0 8 |i Enthalten in  |t American journal of transplantation  |d [Amsterdam] : Elsevier, 2001  |g 12(2012), 7, Seite 1855-1865  |h Online-Ressource  |w (DE-627)328318353  |w (DE-600)2045621-9  |w (DE-576)094404267  |x 1600-6143  |7 nnas  |a A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation PROTECT 
773 1 8 |g volume:12  |g year:2012  |g number:7  |g pages:1855-1865  |g extent:11  |a A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation PROTECT 
856 4 0 |u http://dx.doi.org/10.1111/j.1600-6143.2012.04049.x  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-6143.2012.04049.x  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181119 
993 |a Article 
994 |a 2012 
998 |g 1022937995  |a Schmidt, Jan  |m 1022937995:Schmidt, Jan  |d 50000  |e 50000PS1022937995  |k 0/50000/  |p 20 
998 |g 1022604244  |a Schemmer, Peter  |m 1022604244:Schemmer, Peter  |d 910000  |d 910200  |e 910000PS1022604244  |e 910200PS1022604244  |k 0/910000/  |k 1/910000/910200/  |p 6 
999 |a KXP-PPN1583833897  |e 3032682037 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Fischer, Lutz","role":"aut","family":"Fischer","given":"Lutz"},{"display":"Schemmer, Peter","role":"aut","family":"Schemmer","given":"Peter"},{"given":"Jan","family":"Schmidt","role":"aut","display":"Schmidt, Jan"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1111/j.1600-6143.2012.04049.x"],"eki":["1583833897"]},"physDesc":[{"extent":"11 S."}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"doi":["10.1111/(ISSN)1600-6143"],"eki":["328318353"],"zdb":["2045621-9"],"issn":["1600-6143"]},"part":{"issue":"7","pages":"1855-1865","text":"12(2012), 7, Seite 1855-1865","volume":"12","year":"2012","extent":"11"},"pubHistory":["1.2001 -"],"recId":"328318353","origin":[{"dateIssuedKey":"2001","publisherPlace":"[Amsterdam] ; Copenhagen ; Oxford [u.a.] ; Oxford [u.a.]","dateIssuedDisp":"2001-","publisher":"Elsevier ; Munksgaard ; Blackwell ; Wiley-Blackwell"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"American journal of transplantation","subtitle":"official journal of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST)","title_sort":"American journal of transplantation"}],"disp":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation PROTECTAmerican journal of transplantation","note":["Gesehen am 16.06.25"]}],"title":[{"title_sort":"randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation","subtitle":"PROTECT","title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation"}],"recId":"1583833897","name":{"displayForm":["L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, P. Schemmer, U. Settmacher, N. Heyne, P.-A. Clavien, F. Muehlbacher, I. Morard, H. Wolters, W. Vogel, T. Becker, M. Sterneck, F. Lehner, C. Klein, G. Kazemier, A. Pascher, J. Schmidt, F. Rauchfuss, A. Schnitzbauer, S. Nadalin, M. Hack, S. Ladenburger and H.J. Schlitt"]},"note":["Gesehen am 10.07.2019"],"origin":[{"dateIssuedDisp":"July 2012","dateIssuedKey":"2012"}]} 
SRT |a FISCHERLUTRANDOMIZED2012 

Ähnliche Einträge